|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table S3. One-year relative survival of pediatric brain and central nervous system cancer overall and by race/ethnicity, United States, cases diagnosed during 2001–2008 | | | | | | | | | | |
|  | Total N=11,302 | | White, non-Hispanic N=7,506 | | Black, non-Hispanic N=1,378 | | Hispanic N=1,951 | | Other, non-Hispanic N=467 | |
| Characteristic | No. | RS (95% CI) | No. | RS (95% CI) | No. | RS (95% CI) | No. | RS (95% CI) | No. | RS (95% CI) |
| **TOTAL** | 11,302 | 89.2 (88.6–89.7) | 7,506 | 90.5 (89.8–91.2) | 1,378 | **86.5 (84.6–88.2)** | 1,951 | **86.8 (85.2–88.3)** | 467 | **85.3 (81.7–88.2)** |
| **Sex** |  |  |  |  |  |  |  |  |  |  |
| Male | 6,153 | 89.4 (88.6–90.1) | 4,151 | 90.7 (89.8–91.6) | 715 | **84.6 (81.7–87.1)** | 1,048 | **87.8 (85.6–89.6)** | 239 | 87.5 (82.6–91.1) |
| Female | 5,149 | 88.9 (88.1–89.8) | 3,355 | 90.3 (89.2–91.3) | 663 | 88.5 (85.8–90.7) | 903 | **85.8 (83.3–87.9)** | 228 | **82.9 (77.4–87.2)** |
| **Age (years)** |  |  |  |  |  |  |  |  |  |  |
| 0–4 | 3,687 | 83.1 (81.8–84.3) | 2,289 | 84.4 (82.9–85.9) | 469 | 79.8 (75.8–83.2) | 772 | 82.4 (79.5–84.9) | 157 | 77.2 (69.8–83.0) |
| 5–9 | 2,818 | 90.6 (89.4–91.6) | 1,867 | 91.8 (90.5–93.0) | 360 | **86.7 (82.7–89.8)** | 483 | 88.4 (85.2–91.0) | 108 | 91.7 (84.6–95.6) |
| 10–14 | 2,560 | 92.8 (91.7–93.7) | 1,765 | 93.8 (92.6–94.9) | 291 | 90.4 (86.4–93.3) | 390 | 91.3 (88.0–93.7) | 114 | **86.9 (79.1–91.9)** |
| 15-19 | 2,237 | 93.4 (92.2–94.3) | 1,585 | 94.1 (92.9–95.2) | 258 | 93.9 (90.2–96.2) | 306 | **89.9 (86.0–92.8)** | 88 | 89.8 (81.3–94.6) |
| **US Census region** |  |  |  |  |  |  |  |  |  |  |
| Northeast | 2,545 | 90.9 (89.7–92.0) | 1,864 | 91.5 (90.2–92.7) | 264 | 91.0 (86.9–93.9) | 326 | 87.2 (83.0–90.4) | 91 | 91.2 (83.2–95.5) |
| Midwest | 2,495 | 89.9 (88.7–91.0) | 1,947 | 91.5 (90.1–92.6) | 257 | **85.7 (80.8–89.5)** | 226 | **83.2 (77.7–87.5)** | 65 | 83.2 (71.6–90.3) |
| South | 3,332 | 88.9 (87.8–89.9) | 2,195 | 90.1 (88.8–91.3) | 716 | **84.9 (82.1–87.4)** | 360 | 91.2 (87.7–93.7) | 61 | **78.7 (66.2–87.1)** |
| West | 2,930 | 87.4 (86.1–88.5) | 1,500 | 88.7 (87.0–90.2) | 141 | 87.3 (80.6–91.8) | 1,039 | 86.0 (83.7–88.0) | 250 | 85.3 (80.2–89.1) |
| **Economic status by countya** |  |  |  |  |  |  |  |  |  |  |
| Bottom 25% | 1,457 | 88.2 (86.4–89.8) | 794 | 90.3 (88.0–92.1) | 272 | 86.6 (81.9–90.1) | 334 | 84.8 (80.5–88.2) | 57 | 87.8 (76.0–94.0) |
| 25%–75% | 6,723 | 89.1 (88.3–89.8) | 4,282 | 90.5 (89.6–91.4) | 908 | **85.8 (83.4–87.9)** | 1,277 | **87.7 (85.8–89.4)** | 256 | **83.7 (78.5–87.7)** |
| Top 25% | 2,806 | 89.5 (88.3–90.6) | 2,152 | 90.4 (89.1–91.6) | 188 | 89.4 (84.1–93.1) | 326 | **85.3 (81.0–88.7)** | 140 | 86.5 (79.6–91.2) |
| **Stage** |  |  |  |  |  |  |  |  |  |  |
| Localized | 8,273 | 91.9 (91.3–92.5) | 5,556 | 93.2 (92.5–93.8) | 1,011 | **88.7 (86.6–90.6)** | 1,361 | **89.9 (88.2–91.4)** | 345 | **88.5 (84.6–91.4)** |
| Regional | 1,371 | 81.5 (79.3–83.4) | 856 | 82.9 (80.2–85.3) | 158 | 79.9 (72.7–85.4) | 302 | 78.5 (73.5–82.8) | 55 | 80.0 (66.8–88.4) |
| Distant | 808 | 74.8 (71.7–77.7) | 534 | 75.9 (72.1–79.3) | 88 | 73.0 (62.3–81.1) | 145 | 74.6 (66.6–80.9) | 41 | 65.9 (49.3–78.2) |
| Unknown | 850 | 88.5 (86.2–90.5) | 560 | 89.5 (86.7–91.8) | 121 | 86.1 (78.5–91.1) | 143 | 87.5 (80.8–91.9) | 26 | 84.7 (64.1–94.0) |
| **Anatomic site** |  |  |  |  |  |  |  |  |  |  |
| Lobe | 2,348 | 91.2 (90.0–92.3) | 1,579 | 93.0 (91.6–94.2) | 292 | **87.1 (82.7–90.5)** | 372 | **87.4 (83.6–90.4)** | 105 | 89.6 (81.9–94.1) |
| Cerebrum | 915 | 82.8 (80.2–85.1) | 591 | 84.1 (80.9–86.9) | 130 | 82.4 (74.7–88.0) | 161 | 78.9 (71.8–84.5) | 33 | 78.8 (60.6–89.3) |
| Ventricle | 642 | 87.6 (84.8–90.0) | 411 | 89.9 (86.5–92.4) | 71 | 88.8 (78.8–94.3) | 135 | 84.5 (77.2–89.6) | 25 | **64.0 (42.2–79.4)** |
| Cerebellum | 2,956 | 93.4 (92.4–94.2) | 1,992 | 94.3 (93.2–95.3) | 317 | 91.9 (88.3–94.4) | 516 | 91.5 (88.8–93.6) | 131 | 90.1 (83.5–94.1) |
|  |  |  |  |  |  |  |  |  |  |  |

Supplementary Table S3 (continued).

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Brain stem | 1,438 | | 83.1 (81.0–84.9) | | 952 | | 84.2 (81.7–86.4) | | 164 | | 77.6 (70.3–83.2) | | 267 | 83.6 (78.5–87.5) | 55 | 78.2 (64.8–87.0) |
| Other brain | 2,083 | | 87.8 (86.3–89.1) | | 1,342 | | 88.9 (87.1–90.5) | | 286 | | 85.8 (81.2–89.4) | | 374 | 85.6 (81.6–88.8) | 81 | 85.3 (75.5–91.4) |
| Other CNS | 920 | | 90.6 (88.6–92.4) | | 639 | | 91.8 (89.4–93.7) | | 118 | | 87.5 (79.9–92.3) | | 126 | 89.0 (82.0–93.3) | 37 | 86.5 (70.6–94.2) |
| **Histologyb** |  | |  | |  | |  | |  | |  | |  |  |  |  |
| Pilocytic astrocytoma | 3,480 | | 98.6 (98.1–98.9) | | 2,423 | | 98.8 (98.3–99.2) | | 409 | | 99.3 (97.7–99.8) | | 538 | **96.9 (95.0–98.1)** | 110 | 99.1 (93.4–99.9) |
| Diffuse astrocytoma | 1,196 | | 93.1 (91.5–94.4) | | 825 | | 94.1 (92.3–95.5) | | 142 | | 89.6 (83.2–93.7) | | 185 | 91.4 (86.3–94.7) | 44 | 93.3 (80.3–97.8) |
| Anaplastic astrocytoma | 355 | | 68.8 (63.7–73.3) | | 226 | | 73.5 (67.2–78.8) | | 49 | | 55.2 (40.3–67.8) | | ~ | 64.7 (52.1–74.8) | ~ | ~ |
| Unique astrocytoma variants | 213 | | 96.3 (92.7–98.1) | | 132 | | 97.8 (93.1–99.3) | | 39 | | 100.0 | | ~ | 89.5 (74.3–95.9) | ~ | ~ |
| Glioblastoma | 541 | | 60.9 (56.6–64.9) | | 325 | | 62.5 (57.0–67.5) | | 96 | | 57.4 (46.9–66.6) | | 87 | 55.2 (44.2–64.9) | 33 | 69.7 (51.0–82.5) |
| Oligodendroglioma | 281 | | 98.3 (95.8–99.3) | | 200 | | 99.0 (96.0–99.8) | | 37 | | 97.4 (81.9–99.6) | | ~ | 97.4 (82.6–99.6) | ~ | ~ |
| Anaplastic Oligodendroglioma | 52 | | 88.5 (76.1–94.7) | | 33 | | 84.9 (67.4–93.4) | | ~ | | ~ | | ~ | ~ | ~ | ~ |
| Oligoastrocytic tumors | 173 | | 93.1 (88.2–96.1) | | 132 | | 92.5 (86.4–95.9) | | ~ | | ~ | | 20 | 100.0 | ~ | ~ |
| Ependymal tumors | 988 | | 93.3 (91.5–94.7) | | 604 | | 94.4 (92.3–96.0) | | 127 | | 91.5 (85.0–95.2) | | 207 | 89.4 (84.4–92.9) | 50 | 100.0 |
| Glioma malignant, not otherwise specified | 548 | | 85.1 (81.8–87.8) | | 382 | | 86.2 (82.3–89.3) | | 65 | | 80.1 (68.1–87.9) | | 82 | 87.9 (78.6–93.3) | 19 | 68.5 (42.8–84.4) |
| Choroid plexus tumors | 105 | | 88.8 (80.9–93.5) | | 56 | | 92.9 (82.1–97.3) | | ~ | | ~ | | 34 | 85.4 (68.2–93.7) | ~ | ~ |
| Neuronal and mixed neuronal glial tumors | 97 | | 90.8 (83.0–95.1) | | 64 | | 92.2 (82.3–96.7) | | 18 | | 94.5 (66.3–99.2) | | ~ | ~ | ~ | ~ |
| Medulloblastoma | 1,680 | | 89.4 (87.8–90.8) | | 1,124 | | 90.2 (88.3–91.8) | | 162 | | 89.6 (83.7–93.4) | | 312 | 87.6 (83.3–90.8) | 82 | 85.4 (75.7–91.4) |
| Peripheral neuroectodermal tumor | 558 | | 76.9 (73.2–80.2) | | 340 | | 80.1 (75.4–83.9) | | 67 | | 67.3 (54.6–77.1) | | 122 | 75.5 (66.8–82.2) | 29 | 69.0 (48.8–82.5) |
| Atypical teratoid/rhabdoid tumor | 288 | | 47.0 (41.1–52.6) | | 178 | | 49.0 (41.5–56.1) | | 42 | | 38.3 (23.8–52.6) | | ~ | 49.2 (35.5–61.5) | ~ | ~ |
| Other embryonal tumors | 227 | | 84.4 (78.9–88.5) | | 144 | | 85.6 (78.7–90.4) | | 38 | | 82.0 (65.4–91.1) | | ~ | 85.1 (69.7–93.1) | ~ | ~ |
| Tumors of meninges | 114 | | 80.8 (72.3–86.9) | | 82 | | 80.6 (70.2–87.6) | | ~ | | ~ | | 17 | 82.4 (54.7–94.0) | ~ | ~ |
| Germ cell tumors and cysts | 307 | | 90.0 (86.0–92.8) | | 175 | | 89.2 (83.6–93.0) | | 26 | | 92.4 (72.5–98.1) | | 74 | 89.3 (79.6–94.5) | 32 | 93.8 (77.2–98.4) |
| Unclassified tumors | 69 | | 71.1 (58.8–80.3) | | 45 | | 75.6 (60.3–85.7) | | 16 | | 75.0 (46.3–89.8) | | ~ | ~ | ~ | ~ |
|  | |  |  | |  | | |  | |  | |  |  |  |  |  |
| Abbreviation: CI, confidence interval; CNS, central nervous system; RS, relative survival.  Supplementary Table S3 (continued).  Data were compiled from 34 population-based registries that participate in the Centers for Disease Control and Prevention’s National Program of Cancer Registries, and meet high-quality data criteria. The registries in the Survival Analysis Dataset cover approximately 67% of the US population. For more information see US Cancer Statistics technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical\_notes/stat\_methods/survival.htm). Suppresses any cell with <16 cases. Per National Program of Cancer Registries complementary cell suppression rules: counts for one or more additional cells must be suppressed if a single cell is suppressed. | | | | | | | | | | | | | | | | |
| Bold indicates non-overlapping 95% confidence intervals when comparing non-Hispanic white to non-Hispanic black, Hispanic, or other, non-Hispanic. | | | | | | | | | | | | | | | | |
| aExcludes 316 missing cases. | |  | |  | |  | |  | |  | |  |  |  |  |  |
| bExcludes histology categories with <16 cases. | | | | | |  | |  | |  | |  |  |  |  |  |